Prostate Cancer: Emerging Concepts. Part II

Annals of Internal Medicine

Volumn 125, Issue 3, 1996, Pages 205-212

  Garnick, Marc B ^a   Fair, William R ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; BLOOD; BRACHYTHERAPY; CRYOSURGERY; ECONOMICS; FINANCIAL MANAGEMENT; HUMAN; IMMUNOLOGY; INCIDENCE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROSTATE TUMOR; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; CRYOSURGERY; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH SUPPORT;

EID: 0030213307     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-3-199608010-00009     Document Type: Article

References (60)

1. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med. 1993;118:804-18.
2. Garnick MB, Fair WR. Prostate cancer: emerging concepts. Part I. Ann Intern Med. 1996;125:118-25.
3. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, et al. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology. 1994;44:29-37.
4. Fair WR, Aprikian AG, Cohen D, Sogani P, Reuter V. Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin Invest Med. 1993;16:516-22.
5. Fair WR, Wang Y, Cohen D, Cookson M, Russo P, Dalbagni G, et al. Neoadjuvant androgen deprivation therapy (ADT) in patients with clinically localized prostate cancer - effect on (+) margins and post-operative PSA [Abstract]. J Urol. 1996;153:313A.
6. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggen RL, Sause WT, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995;45: 616-23.
7. Cleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol. 1996;155:213-9.
8. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMO) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 1995;154:424-8.
9. Aprikian AG, Fair WR, Reuter VE, Sogani P, Herr H, Russo P, et al. Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br J Urol. 1994;74:630-6.
10. Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y, et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer. Urology. 1996: [In press].
11. Thompson IM, Renfer LG, Schow DA, Rozanski RA. pT2 disease following neoadjuvant hormonal therapy is not an artifact as manifested by PSA failure rate [Abstract]. 74th Annual Meeting of the South Central Section of the AUA. Kansas City, MO; 8-12 September 1995:138.
12. Sullivan L, Gleave M, Goldenberg L, Bruchovsky N, Jones EC. Long-term neoadjuvant hormonal therapy prior to radical prostatectomy in localized prostate cancer [Abstract]. J Urol. 1994;151:435A.
13. Forman JD, Kumar R, Haas G, Montie J, Porter AT, Mesina CF. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest. 1995;13:8-15.
14. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Loughlin K, Schnall M, et al. A temporal analysis of postoperative prostate specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy. Urology. 1996: [In press].
15. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski J, et al. A multivariate analysis of clinical and pathological factors which predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol. 1995;154:131-8.
16. Israeli RS, Miller WH Jr, Su SL, Powell CT, Fair WR, Samadi DS, et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res. 1994; 54:6306-10.
17. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, et al. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Onc. 1994;12:2634-9.
18. Moreno JG, Croce M, Fischer R, Monne M, Vihko P, Mulholland SG, et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res. 1992;52:6110-2.
19. Fair WR, Israeli RS, Wang Y, Nawabi MD, Edwards ET, Heston WD. Neoadjuvant androgen-deprivation therapy (ADT) prior to radical prostatectomy results in a significantly decreased incidence of residual micrometastatic disease as detected by nested RT-PCR with PSM primers [Abstract]. J Urol. 1995;153:391A.
20. Oliver RT. Does surgery disseminate or accelerate cancer? Lancet. 1995;346: 1506-7.
21. Eschwege P, Dumas F, Blanchet P, Le Maire V, Benoit G, Jardin A, et al. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet. 1995;346:1528-30.
22. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227-30.
23. Zelefsky MJ, Leibel SA, Kutcher GJ, Kelson S, Ling CC, Fuks Z. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer Journal Scientific American. 1996;1:142-50.
24. Leibel SA, Heimann R, Kutcher GJ, Zelefsky MJ, Burman CM, Melian E, et al. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study. Int J Radiat Oncol Biol Phys. 1994;28:55-65.
25. Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Kelson S, Fuks Z. Three dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a Phase I dose escalation study. J Urol. 1994;152: 1792-8.
26. Epstein BE, Hanks GE. Radiation therapy techniques and dose selection in the treatment of prostate cancer. Semin Radiat Oncol. 1993;3:179-86.
27. Sandler HM, McShan DL, Lichter AS. Potential improvement in the results of irradiation for prostate carcinoma using improved dose distribution. Int J Radiat Oncol Biol Phys. 1991;22:361-7.
28. Vijayakumar S, Awan A, Karrison T, Culbert H, Chan S, Kolker J, et al. Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques. Int J Radiat Oncol Biol Phys. 1993; 25:359-71.
29. Bijhold J, Lebesque JV, Hart AA, Vijlbrief RE. Maximizing setup accuracy using portal images as applied to a conformal boost technique for prostatic cancer. Radiother Oncol. 1992;24:261-71.
30. Roach M 3d, Pickett B, Rosenthal SA, Verhey L, Phillips TL. Defining treatment margins for six field conformal irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28:267-75.
31. Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology. 1995;45:624-32.
32. Babaian RJ, Kojima M, Saitoh M, Ayala AG. Detection of residual prostate cancer after external radiotherapy. Role of prostate specific antigen and transrectal ultrasonography. Cancer. 1995;75:2153-8.
33. Zelefsky MJ, Leibel SA, Wallner KE, Whitmore WF Jr, Fuks Z. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J Clin Oncol. 1995;13:459-63
34. Zeitman AL, Coen JJ, Dallow KC, Shipley WU. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys. 1995;32:287-92.
35. Lee WR, Hanks GE, Schultheiss TE, Cori BW, Hunt MA. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate specific-antigen-driven outcome analysis. J Clin Oncol. 1995;13:464-9.
36. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiation Oncology Biol Phys. 1995;32:293-306.
37. Wallner K, Roy J, Zalefsky M, Fuks Z, Harrison L. Short-term freedom from disease progression after 1-125 prostate implantation. Int J Radiat Oncol Biol Phys. 1994;30:405-9.
38. D'Amico AV, Coleman MC. The role of interstitial radiotherapy in the management of clinically organ confined prostate cancer: the jury is still out. J Clin Oncol. 1996;14:304-15.
39. Gage AA. Cryosurgery in the treatment of cancer. Surg Gynecol Obstet 1992;174:73-92.
40. Miller RJ, Cohen JK, Merlotti LS. Percutaneous transperineal cryosurgical ablation of the prostate for the primary treatment of clinical stage C adenocarcinoma of the prostate. Urology. 1994;44:170-4.
41. Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993;72:1291-9.
42. Cox RL, Crawford ED. Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate. Urology. 1995;45:932-5.
43. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:1566-72.
44. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for antiandrogen withdrawal syndrome. Urology. 1994;43 408-10.
45. Bissada NK, Kaczmarek AT. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol. 1995;153:1944-5.
46. Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol. 1995;153: 1946-7.
47. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology. 1995;45:745-53.
48. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet. 1995;346:265-9.
49. Waxman J, Pandha H. Anti-androgens in treatment of prostate cancer [Letter]. Lancet. 1995;346:1030-1.
50. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332:1393-8.
51. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83-90.
52. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-52.
53. Lange PH, Lightner DJ, Medini E, Reddy PK, Vessella RL. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol. 1990;144:927-32.
54. Flanders WD. Prostate cancer epidemiology. Prostate. 1984;5:621-9.
55. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer Cancer. 1993;71(3 Suppl): 933-8.
56. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol. 1989;141:1091-4.
57. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150(2 Pt 1):379-85.
58. Gaziano JM, Hennekens CH. Dietary fat and risk of prostate cancer [Editorial]. J Natl Cancer Inst. 1995;87:1427-8.
59. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst. 1995;87:1456-62.
60. Carter BS, Carter HB, Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate. 1990;16:187-97.